spacer
home > epc > autumn 2008 > future functions
PUBLICATIONS
European Pharmaceutical Contractor

Future Functions

It is nearly 20 years since the first commercial imaging core laboratory was founded. Today, there are numerous commercial imaging core laboratories, numerous international imaging biomarker meetings and regulatory guidance documents to support the use of imaging in drug development. Many academic, government and commercial entities have contributed to the growth of this approach, which has become a mainstream tool for the development of numerous therapeutic drugs.

Medical imaging endpoints are accepted in many clinical trials, and when included in the study design, the FDA requires the implementation of a central, independent image review process. The proliferation of medical imaging endpoints and the resulting management, analysis and submission of medical imaging data has fostered the healthy growth of the medical imaging core lab industry, both for commercial and academic labs. The increase in the number of labs and studies for which they provide services led to a somewhat varied set of documentation and implementation of various technology methods for what is a largely consistent undertaking. Pharmaceutical trial sponsors and the FDA initiated the desire for standardisation in these trials, and DIA has provided the leadership needed to obtain collaboration from all affected parties.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
James Conklin is the Senior Vice President for medical and scientific affairs at ICON Medical Imaging. James is a John Hopkins-trained research physician with undergraduate and graduate training in electrical/computer engineering and a Masters degree in Management. He has been a Professor of Radiology at several medical schools, published over 100 scientific papers and edited four books. One of the textbooks, Imaging Techniques in Biology and Medicine, published by Academic Press in 1987, provided the technical foundation for Bio-Imaging Technologies, Inc. He is board certified in both internal medicine and nuclear medicine.
spacer
James Conklin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

A new market reference added to Safe’n’Sound®, our passive safety device platform

Safe’n’Sound® is on the market in Europe with a newly registered injectable medication. The commercial launch of HULIO™ (Adalimumab Biosimilar) was initiated in selected European markets on October 19,2018. Hulio™, developed by Fujifilm Kyowa Kirin Biologics Co., Ltd. and marketed in the European Union by Mylan N.V. is approved as a biosimilar for the same indications as the reference product, Humira®.
More info >>

White Papers

Spotlight on Quality in Study Startup

Oracle Health Sciences

This white paper addresses the growing interest in quality in clinical trial execution and how workflows play an essential role by building in the steps needed to comply with TMF guidelines, reducing downstream problems. This proactive strategy limits issues caused by siloes, yielding process improvements measurable by performance metrics.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement